Skip to main content

Advertisement

SpringerLink
Log in

Bevacizumab treatment leads to observable morphological and metabolic changes in brain radiation necrosis

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

We investigated morphological and metabolic changes of radiation necrosis (RN) of the brain following bevacizumab (BEV) treatment by using neuroimaging. Nine patients with symptomatic RN, who had already been treated with radiation therapy for malignant brain tumors (6 glioblastomas, 1 anaplastic oligodendroglioma, and 2 metastatic brain tumors), were enrolled in this prospective clinical study. RN diagnosis was neuroradiologically determined with Gd-enhanced MRI and 11C-methionine positron emission tomography (MET-PET). RN clinical and radiological changes in MRI, magnetic resonance spectroscopy (MRS) and PET were assessed following BEV therapy. Karnofsky performance status scores improved in seven patients (77.8 %). Both volumes of the Gd-enhanced area and FLAIR-high area from MRI decreased in all patients after BEV therapy and the mean size reduction rates of the lesions were 80.0 and 65.0 %, respectively. MRS, which was performed in three patients, showed a significant reduction in Cho/Cr ratio after BEV therapy. Lesion/normal tissue (L/N) ratios in MET- and 11C-choline positron emission tomography (CHO-PET) decreased in 8 (89 %) and 9 patients (100 %), respectively, and the mean L/N ratio reduction rates were 24.4 and 60.7 %, respectively. BEV-related adverse effects of grade 1 or 2 (anemia, neutropenia and lymphocytopenia) occurred in three patients. These results demonstrated that BEV therapy improved RN both clinically and radiologically. BEV therapeutic mechanisms on RN have been suggested to be related not only to the effect on vascular permeability reduction by repairing the blood–brain barrier, but also to the effect on suppression of tissue biological activity, such as immunoreactions and inflammation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Glantz MJ, Burger PC, Friedman AH, Radtke RA, Massey EW, Schold SC Jr (1994) Treatment of radiation-induced nervous system injury with heparin and warfarin. Neurology 44:2020–2027

    Article  CAS  PubMed  Google Scholar 

  2. Kohshi K, Imada H, Nomoto S, Yamaguchi R, Abe H, Yamamoto H (2003) Successful treatment of radiation-induced brain necrosis by hyperbaric oxygen therapy. J Neurol Sci 209:115–117

    Article  PubMed  Google Scholar 

  3. McPherson CM, Warnick RE (2004) Results of contemporary surgical management of radiation necrosis using frameless stereotaxis and intraoperative magnetic resonance imaging. J Neurooncol 68:41–47

    Article  PubMed  Google Scholar 

  4. Presta LG, Chen H, O’Connor SJ, Chisholm V, Meng YG, Krummen L et al (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593–4599

    CAS  PubMed  Google Scholar 

  5. Nordal RA, Nagy A, Pintilie M, Wong CS (2004) Hypoxia and hypoxia-inducible factor-1 target genes in central nervous system radiation injury: a role for vascular endothelial growth factor. Clin Cancer Res 15:3342–3353

    Article  Google Scholar 

  6. Nonoguchi N, Miyatake S, Fukumoto M, Furuse M, Hiramatsu R, Kawabata S et al (2011) The distribution of vascular endothelial growth factor-producing cells in clinical radiation necrosis of the brain: pathological consideration of their potential roles. J Neurooncol 105:423–431

    Article  CAS  PubMed  Google Scholar 

  7. Gonzalez J, Kumar AJ, Conrad CA, Levin VA (2007) Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 67:323–326

    Article  CAS  PubMed  Google Scholar 

  8. Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN et al (2011) Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 79:1487–1495

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Furuse M, Kawabata S, Kuroiwa T, Miyatake S (2011) Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases. J Neurooncol 102:471–475

    Article  PubMed  Google Scholar 

  10. Torcuator R, Zuniga R, Mohan YS, Rock J, Doyle T, Anderson J et al (2009) Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol 94:63–68

    Article  CAS  PubMed  Google Scholar 

  11. Miwa K, Matsuo M, Shinoda J, Oka N, Kato T, Okumura A et al (2008) Simultaneous integrated boost technique by helical tomotherapy for the treatment of glioblastoma multiforme with 11C-methionine PET: report of three cases. J Neurooncol 87:333–339

    Article  PubMed  Google Scholar 

  12. Matsuo M, Miwa K, Tanaka O, Shinoda J, Nishibori H, Tsuge Y et al (2012) Impact of [11C]methionine positron emission tomography for target definition of glioblastoma multiforme in radiation therapy planning. Int J Radiat Oncol Biol Phys 82:83–89

    Article  PubMed  Google Scholar 

  13. Takenaka S, Asano Y, Shinoda J, Nomura Y, Yonezawa S, Miwa K, et al (2014) Comparison of 11C-methionine, 11C-choline, and 18F-fluorodeoxyglucose-PET for distinguishing glioma recurrence from radiation necrosis. Neurol Med Chir (Tokyo). 54(4):280–289

  14. Shinoda J, Yano H, Ando H, Ohe N, Sakai N, Saio M et al (2002) Radiological response and histological changes in malignant astrocytic tumors after stereotactic radiosurgery. Brain Tumor Pathol 19:83–92

    Article  PubMed  Google Scholar 

  15. Amin A, Moustafa H, Ahmed E, El-Toukhy M (2012) Glioma residual or recurrence versus radiation necrosis: accuracy of pentavalent technetium-99 m-di mercaptosuccinic acid [Tc-99 m (v) DMSA] brain SPECT compared to proton magnetic resonance spectroscopy (H1-MRS): initial results. J Neurooncol 106:579–587

    Article  CAS  PubMed  Google Scholar 

  16. Matoba M, Kondou T, Tanaka T, Kitadate M, Oota K, Tonami H (2010) Noninvasive monitoring of radiation-induced early therapeutic response using high-resolution MR imaging and proton MR spectroscopy in VX2 carcinoma. J Radiat Res 51:690–705

    Google Scholar 

  17. Nakajima T, Kumabe T, Kanamori M, Saito R, Tashiro R, Watanabe M et al (2009) Differential diagnosis between radiation necrosis and glioma progression using sequential proton magnetic resonance spectroscopy and methionine positron emission tomography. Neurol Med Chir (Tokyo) 49:394–401

    Article  Google Scholar 

  18. Moravan MJ, Olschowka JA, Williams JP, O’Banion MK (2011) Cranial irradiation leads to acute and persistent neuroinflammation with delayed increases in T-cell infiltration and CD11c expression in C57BL/6 mouse brain. Radiat Res 176:459–473

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Zhao W, Robbins ME (2009) Inflammation and chronic oxdative stress in radiation-induced late normal tissue injury: therapeutic implications. Curr Med Chem 16:130–143

    Article  CAS  PubMed  Google Scholar 

  20. Ogawa T, Shishido F, Kanno I, Inugami A, Fujita H, Murakami M et al (1993) Cerebral glioma: evaluation with methionine PET. Radiology 186:45–53

    Article  CAS  PubMed  Google Scholar 

  21. Aki T, Nakayama N, Yonezawa S, Takenaka S, Miwa K, Asano Y et al (2012) Evaluation of brain tumors using dynamic 11C-methinone-PET. J Neurooncol 109:115–122

    Article  PubMed  Google Scholar 

  22. De Witte O, Goldberg I, Wikler D, Rorive S, Damhaut P, Monclus M et al (2001) Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 95:746–750

    Article  PubMed  Google Scholar 

  23. Herholz K, Hölzer T, Bauer B, Schröder R, Voges J, Ernestus RI et al (1998) 11C-methionine PET for differential diagnosis of low grade gliomas. Neurology 50:1316–1322

    Article  CAS  PubMed  Google Scholar 

  24. Kato T, Shinoda J, Nakayama N, Miwa K, Okumura A, Yano H et al (2008) Metabolic assessment of gliomas using 11C-methionine, 18F-fluorodeoxyglucose, and 11C-choline positron-emission tomography. AJNR Am J Neuroradiol 29:1176–1182

    Article  CAS  PubMed  Google Scholar 

  25. Nariai T, Tanaka Y, Wakimoto H, Aoyagi M, Tamaki M, Ishiwata K et al (2005) Usefulness of l-[methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma. J Neurosurg 103:498–507

    Article  PubMed  Google Scholar 

  26. Ogawa T, Inugami A, Hatazawa J, Kanno I, Murakami M, Yasui N et al (1996) Clinical positron emission tomography for brain tumors: comparison of fludeoxyglucose F 18 and L-methyl-11C-methionine. AJNR Am J Neuroradiol 17:345–353

    CAS  PubMed  Google Scholar 

  27. Tovi M, Lilja A, Bergström M, Ericsson A, Bergström K, Hartman M (1990) Delineation of gliomas with magnetic resonance imaging using Gd-DTPA in comparison with computed tomography and positron emission tomography. Acta Radiol 31:417–429

    Article  CAS  PubMed  Google Scholar 

  28. Ohtani T, Kurihara H, Ishiuchi S, Saito N, Oriuchi N, Inoue T et al (2001) Brain tumour imaging with carbon-11 choline: comparison with FDG PET and gadolinium-enhanced MR imaging. Eur J Nucl Med 28:1664–1670

    Article  CAS  PubMed  Google Scholar 

  29. Kureshi SA, Hofman FM, Schneider JH, Chin LS, Apuzzo ML, Hinton DR (1994) Cytokine expression in radiation-induced delayed cerebral injury. Neurosurgery 35:822–830

    Article  CAS  PubMed  Google Scholar 

  30. Chiang CS, McBride WH, Withers HR (1993) Radiation-induced astrocytic and microglial responses in mouse brain. Radiother Oncol 29:60–68

    Article  CAS  PubMed  Google Scholar 

  31. Tsuyuguchi N, Sunada I, Iwai Y, Yamanaka K, Tanaka K, Takami T et al (2003) Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible? J Neurosurg 98:1056–1064

    Article  PubMed  Google Scholar 

  32. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740

    Article  CAS  PubMed  Google Scholar 

  33. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I et al (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740–745

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M et al (2010) Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 29:142–148

    Article  PubMed Central  PubMed  Google Scholar 

  35. Narayana A, Gruber D, Kunnakkat S, Golfinos JG, Parker E, Raza S et al (2012) A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J Neurosurg 116:341–345

    Article  CAS  PubMed  Google Scholar 

  36. Vredenburgh JJ, Desjardins A, Herndon JE II, Marcello J, Reardon DA, Quinn JA et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722–4729

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Conflict of interest

None declared.

Author information

Authors and Affiliations

  1. Chubu Medical Center for Prolonged Traumatic Brain Dysfunction, Kizawa Memorial Hospital, 630 Shimokobi, Kobi-cho, Minokamo, Gifu, 505-0034, Japan

    Shingo Yonezawa, Kazuhiro Miwa, Jun Shinoda, Yuichi Nomura & Yoshitaka Asano

  2. Department of Clinical Brain Sciences, Gifu University Graduate School of Medicine, Minokamo, Japan

    Shingo Yonezawa, Kazuhiro Miwa, Jun Shinoda, Yuichi Nomura & Yoshitaka Asano

  3. Department of Neurosurgery, Gifu University Graduate School of Medicine, Gifu, Japan

    Shingo Yonezawa, Yuichi Nomura, Noriyuki Nakayama, Naoyuki Ohe, Hirohito Yano & Toru Iwama

Authors
  1. Shingo Yonezawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazuhiro Miwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jun Shinoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yuichi Nomura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshitaka Asano
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Noriyuki Nakayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Naoyuki Ohe
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hirohito Yano
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Toru Iwama
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shingo Yonezawa.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yonezawa, S., Miwa, K., Shinoda, J. et al. Bevacizumab treatment leads to observable morphological and metabolic changes in brain radiation necrosis. J Neurooncol 119, 101–109 (2014). https://doi.org/10.1007/s11060-014-1453-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-014-1453-y

Keywords

Search

Navigation